Arcus Biosciences Inc
Q1 2025 Earnings
Market Reaction
S&P 500 over the same 30 days: +6.87%.
Did RCUS Beat Earnings? Q1 2025 Results
Arcus Biosciences delivered a sharp miss on both the top and bottom lines in Q1 2025, as the clinical-stage oncology company absorbed the reversal of a landmark licensing windfall that had inflated year-ago comparisons. Revenue collapsed 80.7% year over year to $28.00 million, falling 27.47% below the $38.61 million consensus, as license and development services revenue plunged to $20.00 million from $135.00 million in Q1 2024 following the prior year's Gilead agreement milestone. The net loss widened dramatically to $112.00 million, or $1.14 per share, missing the $1.01 consensus estimate by 12.61%, with rising R&D expenses of $122.00 million reflecting accelerated Phase 2 enrollment across its pipeline. On the forward outlook, management guided for full-year 2025 GAAP revenue of $75.00 million to $90.00 million, a range that analysts have already received with skepticism, with recent estimates for the year revised meaningfully lower. The company's $1.00 billion cash position is expected to fund operations through pivotal readouts for its three lead programs, including the PEAK-1 Phase 3 trial in renal cell carcinoma, set to initiate in Q2 2025.
- Revenue decline driven by lower license and development services revenue from Gilead collaboration ($20M vs. $135M in Q1 2024)
- R&D expense increase of $13M driven by higher enrollment in Phase 2 studies and early-stage/preclinical activities
- G&A expense decrease driven by absence of one-time costs related to Third Gilead Agreement Amendment in Q1 2024
- February 2025 underwritten equity offering bolstered cash position
“Beginning with an oral presentation at ASCO for casdatifan in ccRCC, we expect to report a steady stream of data from ARC-20 throughout the remainder of 2025 and into 2026. We believe these data will support our robust development plan for casdatifan across multiple settings. This includes our Phase 3 trial, PEAK-1 in the IO-experienced setting, our clinical trial with AstraZeneca, which will combine casdatifan with their anti-PD-1/CTLA-4 bispecific antibody in the IO-naive setting, and three new cohorts in ARC-20 evaluating casdatifan in first- and second-line ccRCC.”
Arcus Biosciences CEO, on the earnings call
Forward Guidance & Outlook
Arcus expects to recognize GAAP revenue of between $75 million and $90 million for the full year 2025. The company believes its $1.0 billion in cash, cash equivalents and marketable securities, together with available facilities, will be sufficient to fund operations through the initial pivotal readouts for domvanalimab, quemliclustat and casdatifan (including PEAK-1). The PEAK-1 Phase 3 trial is expected to initiate in Q2 2025, with PRISM-1 enrollment completion expected by end of 2025. Multiple data readouts are anticipated through the remainder of 2025 and into 2026.
RCUS YoY Financials
RCUS Revenue by Segment
Figures from SEC filings and company reports. Not investment advice.